Description
The debate highlighted the fundamental challenge that nanobodies typically cannot cross the blood-brain barrier, yet membrane-active modifications might further impair CNS access. This represents a critical feasibility gap for any tau-targeting nanobody therapeutic.
Source: Debate session sess_SDA-2026-04-10-SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 (Analysis: SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1)
Resolution criteria
Gap closes when: (1) An engineered nanobody with a BBB shuttle (e.g., transferrin receptor binding moiety or LRP1 ligand) achieves CNS:plasma ratio >= 0.05 after systemic administration in rodents by quantitative mass spectrometry; and (2) the BBB-crossing variant retains >= 70% of its tau-binding affinity (SPR Kd) and >= 60% of membrane-disrupting activity in a lipid vesicle leakage assay compared to the unmodified nanobody; and (3) a single dose reduces tau seeding in a CNS tau mouse model by >= 25% (p < 0.05, n >= 10/group). Deliverable: PK dataset, binding and activity retention data, and in vivo efficacy result.